Raze Therapeutics Announces Addition of Julian Adams, PhD, George Q. Daley, MD, PhD, and Karen Vousden, PhD, to Scientific Advisory Board


Raze Therapeutics, a leading next generation cancer metabolism company, announced today the expansion of its Scientific Advisory Board (SAB) with the addition of three leaders in oncology drug discovery and development.